Specialist Australian regulatory and clinical-development support from early feasibility and start-up readiness through CTN or CTA, HREC, Local Sponsor, site and ongoing regulatory change.
Tricode can support early Australian feasibility, including assessment of regulatory and start-up requirements, the site landscape, site interest, Local Sponsor needs, timing, GMP and other program-specific considerations.
This may include early site identification and outreach, site capabilities, the likely HREC and governance approach, investigational product considerations, OGTR or IBC implications where relevant, regulatory and document-readiness gaps, and activities that can begin before formal CRO mobilisation.
The Australian workstream can begin before the complete outsourcing model is finalised. Tricode can progress agreed Australian regulatory and start-up activities while sites, CROs and specialist providers are still being considered.
Site relationships. Tricode maintains direct relationships with Australian early-phase and specialist clinical trial sites and networks, providing practical knowledge of site capabilities, start-up expectations and the clinical research environment.
Tricode remains independent of individual sites. Site identification and engagement are guided by the requirements of the particular study rather than a fixed site network or referral model.
For the wider development and market-entry context, see Tricode Clinical’s Strategic Guide to Australian Market Entry.
Clinical trials in Australia that use unapproved therapeutic goods are generally conducted under the Therapeutic Goods Administration’s Clinical Trial Notification (CTN) scheme or Clinical Trial Approval (CTA) scheme. The appropriate route depends on the therapeutic good, the available evidence, the nature of the trial and the capacity of the approving Human Research Ethics Committee (HREC) to assess the proposal.
For international sponsors, the regulatory pathway is only one part of start-up. The Australian trial sponsor, HREC review, institutional governance, trial documentation, TGA interactions and, for some gene therapy or GMO programs, Office of the Gene Technology Regulator (OGTR) requirements need to be planned as connected workstreams.
Tricode provides a specialist Australian interface across those workstreams, helping global and regional teams determine what is required, assign responsibilities clearly and progress the Australian component of the program alongside the sponsor’s selected CRO, sites and specialist providers.
CTN and CTA are different regulatory mechanisms. Tricode helps sponsors assess the pathway against the product and trial circumstances, prepare the required regulatory package and coordinate the TGA and HREC interfaces.
Under the CTN scheme, the TGA does not evaluate clinical trial data at the time of notification. The sponsor must first determine that the trial is eligible for CTN and, where both CTN and CTA may be available, the appropriateness of CTN should be considered with the approving HREC.
The CTA scheme involves TGA evaluation of scientific information about the unapproved therapeutic good before approval to supply it for the trial. The CTA pathway is mandatory in some circumstances, including certain Class 4 biologicals, and may be appropriate where additional TGA evaluation is required.
Good start-up depends on more than completing a notification or application form. The regulatory package must be internally consistent and aligned with the product, protocol, investigator information and Australian operating model.
Tricode can support regulatory assessment and preparation before submission, including confirmation of the proposed pathway, review of Australian-specific requirements, regulatory document preparation or review, and management of questions arising through the TGA or ethics process.
Australian clinical trial start-up involves ethical review as well as TGA requirements. HREC review, site or institutional governance and sponsor regulatory activities may proceed in parallel in some programs, but responsibilities and dependencies need to be mapped carefully.
Tricode supports the regulatory and ethics interface rather than replacing the HREC, site governance team or CRO start-up function. We can coordinate document packages, respond to regulatory and ethics questions, track dependencies and work with the sponsor’s chosen CRO and sites so that Australian requirements are addressed consistently.
Tricode may remain engaged throughout study conduct as an Australian regulatory and clinical development resource, including where the sponsor needs to adjust sites, providers, regulatory strategy or the broader Australian operating model.
The National Statement on Ethical Conduct in Human Research 2025 took effect on 23 June 2026. Study teams should ensure ethics documentation and processes are aligned with the current National Statement and any applicable institutional or jurisdictional requirements.
Every clinical trial conducted in Australia must have a trial sponsor that is an Australian entity. An overseas company cannot itself be the Australian trial sponsor. That makes the local operating model an early regulatory decision for international pharmaceutical and biotechnology organisations.
Where appropriate, Tricode can accept appointment as the Australian clinical trial sponsor or support the sponsor in establishing another suitable Australian sponsor arrangement. The Australian sponsor model can be designed to work alongside the sponsor’s existing CRO, sites and specialist providers.
For the role, operating model and engagement approach, see Australian Local Sponsor and Regulatory Agent support.
For a broader Australian entry perspective, see Tricode Clinical’s Strategic Guide to Australian Market Entry.
Some gene therapy, viral-vector and other genetically modified therapeutic programs require a separate gene-technology pathway assessment. Tricode can support assessment of DNIR, DIR or other treatment under the current framework, IBC coordination where applicable, and alignment with TGA, HREC and site start-up.
Learn more about OGTR and Advanced Therapies regulatory support →
Engagements are scoped around the sponsor’s actual Australian regulatory and start-up gap, with clear responsibilities alongside established CRO, site and internal sponsor teams.
Review the product, protocol, Australian feasibility, site landscape, sponsor structure and evolving outsourcing model.
Assess CTN or CTA, Australian trial sponsor requirements, HREC approach, timing and OGTR implications where relevant.
Prepare or review required documents and coordinate HREC, TGA, Local Sponsor, site and provider interfaces.
Support amendments, additional or replacement sites, provider changes, regulatory strategy and ongoing Australian requirements.
Regulatory information on this page was reviewed on 7 October 2026 against current TGA, NHMRC and OGTR sources. Requirements should be confirmed for the specific product and trial before implementation.
Tell Tricode Clinical where your program stands, whether you are assessing Australia, developing early feasibility, choosing between CTN and CTA, preparing ethics and start-up activities, establishing Australian trial sponsor arrangements or adjusting an ongoing study.
Discuss Australian study start-up Request a Proposal